Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase IV study of monoclonal antibodies for early outpatient COVID-19 treatment
2021-004188-28Phase 4Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Casirivimab + imdevimab with Sotrovimab (2 arms). Primary endpoint: Primary composite endpoint by day 29. Started Sep 2021; status: completed.
02
Drugs
casirivimabimdevimabsotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004188-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004188-28.